Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in a solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY.
Company profile
Ticker
STML
Exchange
Website
CEO
Ivan Bergstein
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
450522567
STML stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
22 Jun 20
EFFECT
Notice of effectiveness
17 Jun 20
EFFECT
Notice of effectiveness
17 Jun 20
EFFECT
Notice of effectiveness
17 Jun 20
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Jun 20
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Jun 20
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Jun 20
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Jun 20
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Jun 20
S-8 POS
Registration of securities for employees (post-effective amendment)
10 Jun 20
Latest ownership filings
Institutional ownership, Q3 2022
13F holders | Current |
---|---|
Total holders | 0 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 0.00 |
Total shares | 0.00 |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|